BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32932171)

  • 21. Evaluation of circulating EBV microRNA BART2-5p in facilitating early detection and screening of nasopharyngeal carcinoma.
    Jiang C; Chen J; Xie S; Zhang L; Xiang Y; Lung M; Kam NW; Kwong DL; Cao S; Guan XY
    Int J Cancer; 2018 Dec; 143(12):3209-3217. PubMed ID: 29971780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy.
    Jin Y; Ye X; Shao L; Lin BC; He CX; Zhang BB; Zhang YP
    Eur J Cancer; 2013 May; 49(7):1619-26. PubMed ID: 23266049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishment and validation of two nomograms to predict the benefit of concurrent chemotherapy in stage II-IVa nasopharyngeal carcinoma patients with different risk factors: Analysis based on a large cohort.
    Sun XS; Xiao BB; Lin C; Liu SL; Chen QY; Tang LQ; Mai HQ
    Cancer Med; 2020 Mar; 9(5):1661-1670. PubMed ID: 31925942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes.
    Nicholls JM; Lee VH; Chan SK; Tsang KC; Choi CW; Kwong DL; Lam KO; Chan SY; Tong CC; So TH; Leung TW; Luk MY; Khong PL; Lee AW
    Br J Cancer; 2019 Oct; 121(8):690-698. PubMed ID: 31527689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment Serum Lactate Dehydrogenase and Metastases Numbers as Potential Determinants of Anti-PD-1 Therapy Outcome in Nasopharyngeal Carcinoma.
    Ali WAS; Huang X; Wu Y; Ma Y; Pan H; Liao J; Yang Z; Hong S; Yang Y; Huang Y; Zhao Y; Fang W; Zhao H; Zhang L
    Cancer Control; 2023; 30():10732748221148912. PubMed ID: 36592162
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of EBV serology and serum cell-free DNA as screening tools for nasopharyngeal cancer: Results of the Singapore NPC screening cohort.
    Tay JK; Siow CH; Goh HL; Lim CM; Hsu PP; Chan SH; Loh KS
    Int J Cancer; 2020 May; 146(10):2923-2931. PubMed ID: 31705522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Joint quantitative measurement of hTERT mRNA in both peripheral blood and circulating tumor cells of patients with nasopharyngeal carcinoma and its clinical significance.
    Fu X; Shen C; Wang H; Chen F; Li G; Wen Z
    BMC Cancer; 2017 Jul; 17(1):479. PubMed ID: 28693532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of the tumor volume reduction rate after neoadjuvant chemotherapy in patients with locoregional advanced nasopharyngeal carcinoma.
    Yang H; Liu Y; Zhang R; Ye Y; Chen Q; Qin Q; Huang L; Li X; Cai R; Tang H; Jiang W
    Oral Oncol; 2020 Nov; 110():104897. PubMed ID: 32679404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment of an integrated model incorporating standardised uptake value and N-classification for predicting metastasis in nasopharyngeal carcinoma.
    Zhang Y; Li WF; Mao YP; Zhou GQ; Peng H; Sun Y; Liu Q; Chen L; Ma J
    Oncotarget; 2016 Mar; 7(12):13612-20. PubMed ID: 26871291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic impact of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in nasopharyngeal carcinoma: A retrospective study of 180 Taiwanese patients.
    Liao LJ; Hsu WL; Wang CT; Lo WC; Cheng PW; Shueng PW; Hsieh CH; Chiu YL; Lin YC
    Clin Otolaryngol; 2018 Apr; 43(2):463-469. PubMed ID: 28950051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Second primary squamous cell carcinoma in patients with nasopharyngeal carcinoma after radiotherapy-Predictors and prognostic factors.
    Wang X; Li Y; Gao Y; Ouyang D; Guo Z
    Head Neck; 2018 Jul; 40(7):1434-1442. PubMed ID: 29522261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum lactate dehydrogenase level is a prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy.
    Turen S; Ozyar E; Altundag K; Gullu I; Atahan IL
    Cancer Invest; 2007 Aug; 25(5):315-21. PubMed ID: 17661206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Usefulness of IGF-1 serum levels as diagnostic marker of nasopharyngeal carcinoma.
    M'hamdi H; Baizig NM; ELHadj OE; M'hamdi N; Attia Z; Gritli S; Gamoudi A; El May MV; A El May
    Immunobiology; 2016 Nov; 221(11):1304-8. PubMed ID: 27312888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of prior cancer on trial eligibility and treatment outcomes in nasopharyngeal carcinoma: Implications for clinical trial accrual.
    Wang YQ; Lv JW; Tang LL; Du XJ; Chen L; Li WF; Liu X; Guo Y; Lin AH; Mao YP; Sun Y; Chen YP; Ma J
    Oral Oncol; 2019 Mar; 90():23-29. PubMed ID: 30846172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating tumor cells: a valuable marker of poor prognosis for advanced nasopharyngeal carcinoma.
    Ou G; Xing S; Li J; Zhang L; Chen S
    Mol Med; 2019 Nov; 25(1):50. PubMed ID: 31729954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of prognostic nutritional index in nasopharyngeal carcinoma: A meta-analysis containing 4511 patients.
    Tu X; Ren J; Zhao Y
    Oral Oncol; 2020 Nov; 110():104991. PubMed ID: 32919361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The risk of second primary tumors in patients with nasopharyngeal carcinoma after definitive radiotherapy.
    Kong L; Lu JJ; Hu C; Guo X; Wu Y; Zhang Y
    Cancer; 2006 Sep; 107(6):1287-93. PubMed ID: 16909425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
    Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
    Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis.
    Wang L; Wu Z; Xie D; Lv S; Xia L; Su Y
    Radiat Oncol; 2020 Jul; 15(1):160. PubMed ID: 32615984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
    Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
    Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.